To address the evolving treatment needs of people living with HIV/AIDS in the poorest and most vulnerable countries, ViiV Healthcare has announced a new series of initiatives, including:
Improving access to medicines by granting generic manufacturers royalty free licenses to the whole portfolio of ViiV Healthcare antiretroviral medicinesExpanding the number of countries that can benefit from this arrangement to include all least developed countries, all low income countries and all of sub-Saharan Africa – that is 80% of all people currently living with HIV
Extending the Not For Profit Price commitment of Viiv’s ARV portfolio with governments and international procurement agencies to all of these 69 countries
Making all patents available to generic manufacturers in these countries for all future pipeline developments, such as the novel integrase inhibitor jointly under development Shionogi – ViiVHealthcare, LLC.
-At ViiV Healthcare we wanted to go one step further in addressing the HIV/AIDS crisis and supporting access for people living with HIV in the worst affected countries. As a company totally focused and dedicated to tackling this epidemic we are passionately committed to thinking and acting differently and taking new steps to expand access to medicines,- said Dr Dominique Limet, CEO of ViiV Healthcare. -This is why we have taken steps to make our entire portfolio and our pipeline available through our royalty-free voluntary licensing and not-for-profit initiatives.- ViiVHealthcare acknowledges the contribution of Shire Pharmaceuticals Group plc, which has a Master Licence agreement with ViiVHealthcare, for products containing lamivudine; and of Shionogi co-developer of the integrase inhibitor with ViiVHealthcare that have also agreed to waive its rights to royalty payments in order to improve access for these products.
Global Health Progress supports raised awareness and mobilized resources to address health challenges in the developing world, including access to drugs, by bringing local leaders together with international health experts, policymakers, donor governments, and the private sector.